Related Experiment Video
Updated: Jul 2, 2025
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Precision Oncology in Hepatopancreatobiliary Cancer Surgery
Timothy E Newhook1, Susan Tsai2, Funda Meric-Bernstam3
1Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract:
Advances in technology have allowed for the characterization of tumors at the genomic, transcriptomic, and proteomic levels. There are well-established targets for biliary tract cancers, with exciting new targets emerging in pancreatic ductal adenocarcinoma and potential targets in hepatocellular carcinoma. Taken together, these data suggest an important role for molecular profiling for personalizing cancer therapy in advanced disease and need for design of novel neoadjuvant studies to leverage these novel therapeutics perioperatively in the surgical patient.
Insights
Molecular profiling advances cancer treatment. New genomic, transcriptomic, and proteomic targets in biliary tract, pancreatic, and liver cancers personalize therapy for advanced disease.
Area of Science:
- Oncology
- Genomics
- Proteomics
Background:
- Technological advancements enable comprehensive tumor characterization at genomic, transcriptomic, and proteomic levels.
- Established therapeutic targets exist for biliary tract cancers.
- Emerging targets show promise for pancreatic ductal adenocarcinoma and hepatocellular carcinoma.
Purpose of the Study:
- To highlight the role of molecular profiling in personalizing cancer therapy for advanced malignancies.
- To emphasize the need for novel neoadjuvant studies incorporating emerging therapeutics in surgical patients.
Main Methods:
- Genomic, transcriptomic, and proteomic analyses of tumors.
- Review of current and emerging therapeutic targets in gastrointestinal cancers.
Main Results:
- Identification of well-established targets in biliary tract cancers.
- Discovery of novel targets in pancreatic ductal adenocarcinoma.
- Potential therapeutic targets identified in hepatocellular carcinoma.
Conclusions:
- Molecular profiling is crucial for personalized cancer therapy in advanced stages.
- Neoadjuvant studies are needed to integrate novel therapeutics into perioperative care for surgical patients.
More Related Videos
12:34Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
Published on: January 3, 2020
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024